Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05576103 · ClinicalTrials.gov registry record
Longitudinal Prospective Study of Neurocognition & Neuroimaging in Primary BT Patients
A clinical trial of Glioma and Meningioma, sponsored by Jona Hattangadi-Gluth.
- Recruiting
- Registry status
- 250
- Enrollment target
- 1
- Study location
NCT05576103 is a study of Glioma and Meningioma that is actively recruiting participants, run by Jona Hattangadi-Gluth. The registered enrollment target is 250 participants, above the 207-participant average among 87 other Glioma trials with a reported enrollment target (21% higher). The trial reports 1 study location across 1 state.
The verdict
NCT05576103, a study of Glioma and Meningioma, is actively recruiting participants, sponsored by Jona Hattangadi-Gluth.
- RECRUITING
- Registry status
- 250 participants
- Enrollment target
- 1
- Study location
Study Summary
In this proposal, the investigators introduce a novel, translational study to prospectively examine primary brain tumor patients undergoing fractionated radiation therapy to the brain. Quantitative neuroimaging, radiation dose information, and directed neurocognitive testing will be acquired through this study to improve understanding of cognitive changes associated with radiation dosage to non-targeted tissue, and will provide the basis for evidence-based cognitive- sparing brain radiotherapy.
Conditions Studied
Study Locations (1)
California
- Moores Cancer Center - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2015-01 |
| Est. Completion | 2026-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05576103
The ClinicalTrials.gov registry entry for NCT05576103 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 207-participant average among 87 other Glioma trials with a reported enrollment target (21% higher). The listed sponsor is Jona Hattangadi-Gluth, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Glioma appearing as the primary indexed condition, and to 0 interventions.
NCT05576103 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT05576103 about?
NCT05576103 is a clinical study titled "Longitudinal Prospective Study of Neurocognition & Neuroimaging in Primary BT Patients". In this proposal, the investigators introduce a novel, translational study to prospectively examine primary brain tumor patients undergoing fractionated radiation therapy to the brain. Quantitative neuroimaging, radiation dose information, and directed neurocognitive testing will be acquired through...
What is the current status of trial NCT05576103?
This trial is currently recruiting. The enrollment target is 250 participants. The study started on 2015-01. Estimated completion is 2026-12.
What conditions does trial NCT05576103 study?
This clinical trial studies the following conditions: Glioma, Meningioma, Primary Brain Tumor, Schwannoma.
Who is sponsoring clinical trial NCT05576103?
This trial is sponsored by Jona Hattangadi-Gluth, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05576103 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma
RECRUITING · Phase 2
-
Tumor Treating Fields for the Treatment of Brainstem Gliomas
RECRUITING · NA
-
Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
RECRUITING · Phase 4
-
Cognitive Changes of IDH-mutant and IDH-wildtype Glioma Patients After Chemoradiotherapy With Radiation Dose to the Resting State Networks
RECRUITING
-
Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors
RECRUITING · Phase 1
-
Sequential Treatments or Combinations Including Dasatinib, Quercetin, Fisetin and/or Temozolomide for the Treatment of Previously Treated Glioma With Residual Disease
RECRUITING · Early Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.